JAK2 and MPL mutations are associated with BCR-ABL negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [1–3]. This evidence concerns the gene JAK2 and acquired polycythemia vera.